The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Clone of Congressionally Directed Medical Research Programs (CDMRP) -- Melanoma Research Program --Translational Research Award
The FY19 MRP Translational Research Award supports hypothesis-driven, translational, highimpact research. The Translational Research Award mechanism encourages applications with mature research projects that specifically focus on critical scientific or clinical melanoma issues, which, if successfully addressed, have the potential to make a major impact. Important factors under consideration will be continuity of research, clinical applicability, and leveraging of clinical samples from clinical trials and/or biorepositories. The Translational Research Award supports identifying scientific outcomes, through rigorous, robust research, that are translatable toward treatment and/or preventive strategies. Research proposed should aim to accelerate promising findings toward clinical applicability and leverage research results to maximize impact. Proposed studies should focus on the commonalities in melanoma research to advance the understanding of the field The Translational Research Award is not intended to study research into established late-stage disease models, clinical utility of PD-1 in combination with other therapeutics, or established cell lines.
• Required Pre-Application Deadline: July 26, 2019
• Application Submission Deadline: October 23, 2019
Areas of Interest
To be considered for funding, applications for the FY19 MRP Translational Research Award must address at least one of the FY19 MRP Focus Areas:
• Precursor Lesions, Melanomagenesis, Host Factors, and the Tumor Microenvironment (e.g., melanoma instigators, ultraviolet [UV] exposure, other instigators)
• Melanoma Primary Tumor Evolution (e.g., dormancy, heterogeneity, metabolism, epigenetic dysregulation, cell death)
• Therapeutic Prevention (e.g. interruption of disease progression, recurrence)
• Minimal Residual Disease (e.g. chemoprevention, micro-metastasis)
• Rare Melanomas (e.g., uveal, acral, leptomeningeal disease, pediatric, adolescent and young adult [AYA], mucosal)
Independent investigators at or above the level of Assistant Professor (or equivalent) are eligible to be named as the PI on the application.
The anticipated direct costs budgeted for the entire period of performance for an FY19 MRP Translational Research Award will not exceed $600,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.